TNFRSF4 and B-cell non-Hodgkin lymphoma: In another preclinical study, human NK cells showed transiently upregulated CD134 in coculture with Rituximab-opsonized Ramos B cell lymphoma cells, and after stimulation with agonistic anti-CD134 mAb, demonstrated enhanced cytotoxicity and cytokine release in human NK cells [96].